Abbvie Deutschland Gmbh and Co Kg

Abbvie Inc.

Abbott Gmbh & Co Kg

Ute Lander

Bernd Liepold

Kennan C Marsh

Jörg Breitenbach

Jörg Rosenberg

Christoph Schmidt

Ulrich Westedt

Gunther Berndl

Yi Gao

Joerg Breitenbach

Ping Tong

Nancy E Sever

Harald Hach

Adivaraha Jayasankar

Marius Naris

Katrin Schneider

Constanze Obermiller

Colleen Garrett

Juergen Weis

Benedikt Steitz

Michael Simon

Dietrich Granzow

Thomas Mueller

Samuel Kyeremateng

Regina Reul

Katharina Asmus

Donghua Zhu

Michael Siimon

Jorg Rosenberg

Kennan Marsh

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.

Solid retard formulations based on solid dispersions

Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono-and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.

Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same

A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.

Growing community of inventors

Dannenfels, Germany

Ute Lander